Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) and ...

The ASX 300 stock highlights that ~92% of all evaluable patients have a programmed death-ligand 1 (PD-L1) Tumor Proportion ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

On May 12th the president signed an executive order that seeks to force drugmakers to reduce their prices in America to align ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some of the most expensive medications.